Mitchell J et al. American Society of Hypertension 21st Annual Scientific Meeting and Exposition; May 16-20, 2006; New York, NY. Abstract P-209.

1
Mean change from baseline in 24-hour mean
ambulatory systolic (MASBP) and diastolic BP
(MADBP) by treatment group
Measure Placebo Aliskiren 150 mg/d Aliskiren 300 mg/d Aliskiren 600 mg/d
Mean change in MASBP (mm Hg) 1.61 -6.55 -5.96 -7.43
Mean change in MADBP (mm Hg) 1.75 -9.63 -8.77 -9.92
Least squares mean
Mitchell J et al. American Society of
Hypertension 21st Annual Scientific Meeting and
Exposition May 16-20, 2006 New York, NY.
Abstract P-209.
2
Change from baseline in mean sitting diastolic
blood pressure (MSDBP) and mean sitting systolic
blood pressure (MSSBP) by treatment group
End point Placebo Aliskiren 300 mg/d Hydrochlorothiazide 25 mg/d Aliskiren 300 mg/d hydrochlorothiazide 25 mg/d
Change in MSDBP (mm Hg) -6.9 -10.3 -9.4 -14.3
Change in MSSBP (mm Hg) -7.5 -15.7 -14.3 -21.2
Villamil A et al. American Society of
Hypertension 21st Annual Scientific Meeting and
Exposition May 16-20, 2006 New York, NY.
Abstract P-228.